Westfield Capital Management Co. LP Has $58.62 Million Stock Holdings in GeneDx Holdings Corp. $WGS

Westfield Capital Management Co. LP decreased its stake in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 7.7% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 544,094 shares of the company’s stock after selling 45,094 shares during the quarter. Westfield Capital Management Co. LP’s holdings in GeneDx were worth $58,621,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. Royal Bank of Canada increased its holdings in GeneDx by 30.2% during the first quarter. Royal Bank of Canada now owns 29,479 shares of the company’s stock worth $2,611,000 after buying an additional 6,840 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of GeneDx by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company’s stock valued at $677,000 after acquiring an additional 453 shares during the period. NewEdge Advisors LLC increased its stake in shares of GeneDx by 270,700.0% during the 1st quarter. NewEdge Advisors LLC now owns 2,708 shares of the company’s stock worth $240,000 after purchasing an additional 2,707 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of GeneDx by 67.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company’s stock valued at $2,500,000 after purchasing an additional 11,375 shares during the period. Finally, AlphaQuest LLC lifted its stake in GeneDx by 351.5% in the 2nd quarter. AlphaQuest LLC now owns 763 shares of the company’s stock valued at $70,000 after purchasing an additional 594 shares during the last quarter. Institutional investors and hedge funds own 61.72% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Jefferies Financial Group set a $150.00 price target on GeneDx in a research report on Monday. Wells Fargo & Company raised GeneDx from an “equal weight” rating to an “overweight” rating and set a $155.00 target price on the stock in a report on Monday, February 9th. Piper Sandler restated an “overweight” rating and issued a $130.00 price target (down from $160.00) on shares of GeneDx in a research note on Tuesday. Zacks Research raised shares of GeneDx from a “hold” rating to a “strong-buy” rating in a research report on Wednesday. Finally, BTIG Research dropped their price objective on shares of GeneDx from $200.00 to $170.00 and set a “buy” rating on the stock in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $150.71.

GeneDx Stock Up 3.1%

WGS stock opened at $81.38 on Friday. GeneDx Holdings Corp. has a fifty-two week low of $55.17 and a fifty-two week high of $170.87. The company has a debt-to-equity ratio of 0.16, a current ratio of 2.46 and a quick ratio of 2.59. The stock has a market capitalization of $2.35 billion, a price-to-earnings ratio of -108.51 and a beta of 2.00. The business’s fifty day moving average price is $107.66 and its two-hundred day moving average price is $123.86.

GeneDx (NASDAQ:WGS) last released its quarterly earnings results on Monday, February 23rd. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.11 by $0.03. GeneDx had a negative net margin of 4.92% and a positive return on equity of 14.73%. The business had revenue of $120.99 million for the quarter, compared to the consensus estimate of $120.80 million. On average, equities analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Insider Transactions at GeneDx

In other GeneDx news, CFO Kevin Feeley sold 3,855 shares of GeneDx stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $143.87, for a total value of $554,618.85. Following the completion of the transaction, the chief financial officer directly owned 8,731 shares of the company’s stock, valued at $1,256,128.97. The trade was a 30.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Katherine Stueland sold 10,857 shares of the firm’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $143.89, for a total value of $1,562,213.73. Following the completion of the transaction, the chief executive officer owned 14,237 shares in the company, valued at $2,048,561.93. The trade was a 43.27% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 30,961 shares of company stock valued at $3,933,831. 29.60% of the stock is currently owned by company insiders.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.